Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer
Zai Lab reported first Phase 1b data for zocilurtatug pelitecan (zoci, formerly ZL-1310) plus atezolizumab in first-line extensive-stage small cell lung cancer, showing a confirmed objective response rate of 81.8% (27/33) and an estimated 6-month PFS rate of 81.9% at the 1.6 mg/kg RP3D. In patients with at least six months of follow-up (n=15), median PFS and duration of response were not yet reached after a median 10 months of follow-up, and the doublet showed a favorable safety profile with Grade ≥3 zoci-related AEs in only 9.1% of patients versus roughly 60% for current platinum-based standard of care.
Key figures
- Drug Name
- zocilurtatug pelitecan (zoci, formerly ZL-1310)
- Phase Of Trial
- Phase 1b; Phase 3 planned
- Rp3d dose
- 1.6 mg/kg
- Orr doublet
- 81.8% (27/33)
- Orr triplet
- 92.3% (n=13)
- Median followup
- 10 months
- Six month pfs rate
- 81.9%
- Grade3plus doublet teaes
- 21.2%
- Grade3plus triplet teaes
- 76.9%
- Grade3plus zoci related aes
- 9.1% (3/33)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.